Research and reviews on other medications

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-15-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

08-31-2018 | Retinopathy | Article

Could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

09-24-2018 | Atherosclerosis | Article

Prevention of atherothrombotic events in patients with diabetes mellitus: From antithrombotic therapies to new-generation glucose-lowering drugs

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2

09-05-2018 | Anti-hypertensive medications | Article

Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials

Leiter LA et al. Diabet Med 2018. doi: 10.1111/dme.13817

06-30-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

06-26-2018 | Devices and technology | Review | Article

Technology in the management of type 1 diabetes mellitus: Current status and future prospects

Tauschmann M Hovorka R. Nat Rev Rheumatol 2018. doi: 10.1038/s41574-018-0044-y

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-16-2018 | Risk factors | Review | Article

Methods for measuring risk for type 2 diabetes in youth: The oral glucose tolerance test (OGTT)

Chen ME, Aguirre RS, Hannon TS. Curr Diab Rep 2018; 18: 51. doi: 10.1007/s11892-018-1023-3

06-15-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

06-15-2018 | Diet | Article

Association between dietary protein intake and type 2 diabetes varies by dietary pattern

Ke Q et al. Diabetol Metab Syndr 2018; 10: 48. doi: 10.1186/s13098-018-0350-5

06-14-2018 | Dulaglutide | Article

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicenter, open-label, randomized trial

Tuttle KR et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30104-9

06-11-2018 | Diabetic foot | Article

Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial

Park KH et al. Diabetes Res Clin Prac 20184 142: 335–344. doi: 10.1016/j.diabres.2018.06.002

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

06-08-2018 | Cardiovascular outcomes | Article

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: A 7-year follow-up study

Blanc-Bisson C et al. Cardiovasc Diabetol 2018; 17: 82. doi: 10.1186/s12933-018-0718-8

06-04-2018 | Neonatal diabetes | Article

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: An international cohort study

Bowman P et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30106-2

05-28-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

05-22-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9